Clinical Trial Update: Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial of FT-2102 in IDH1-mutant acute myeloid leukemia and myelodysplastic syndrome, evaluating FT-2102 with or without azacitidine or cyta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CYTARABINE (CYTARABINE)
• FT-2102

Snippet

Sponsor: Forma Therapeutics, Inc. | Conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-26